From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children wi...
Insulet Corporation (PODD)
Last insulet corporation earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insulet.com/investor-relations
Company Research
Source: Yahoo! Finance
pump technology with its Omnipod ® brand of products, today announced the Company will present results from its multinational Randomized Controlled Trial to Demonstrate the Efficacy of Omnipod 5 Compared with Multiple Daily Injections for Treatment of Type 1 Diabetes (RADIANT). The results will be shared at the 18 th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place March 19 – 22, 2025 in Amsterdam, the Netherlands, and online. The study assessed changes in HbA1c as well as time in target glucose range (TIR) for people aged 4 to 70 years living with type 1 diabetes in France, the U.K., and Belgium using Omnipod 5, compared with those using multiple daily injections (MDI) with a continuous glucose monitor (CGM). RADIANT is the first randomized controlled trial to assess the direct transition from MDI to an automated insulin delivery (AID) system in adults and children who were not previously achieving clinical targets for HbA1c with MDI.
Show less
Read more
Impact Snapshot
Event Time:
PODD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PODD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PODD alerts
High impacting Insulet Corporation news events
Weekly update
A roundup of the hottest topics
PODD
News
- Insulet (NASDAQ:PODD) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Insulet (NASDAQ:PODD) had its price target lowered by analysts at Truist Financial Corporation from $412.00 to $390.00. They now have a "buy" rating on the stock.MarketBeat
- Insulet (NASDAQ:PODD) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Insulet (NASDAQ:PODD) had its price target raised by analysts at Canaccord Genuity Group Inc. from $432.00 to $450.00. They now have a "buy" rating on the stock.MarketBeat
- Insulet (NASDAQ:PODD) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $370.00 price target on the stock.MarketBeat
PODD
Earnings
- 11/6/25 - Beat
PODD
Sec Filings
- 12/19/25 - Form 8-K
- 12/17/25 - Form 8-K
- 12/16/25 - Form 4
- PODD's page on the SEC website